nivolumab

January 24, 2019

Imbruvica-Opdivo Combination Shows Promise in Richter’s Transformation

News

A combination of Imbruvica (ibrutinib) and Opdivo (nivolumab) reduced tumor burden in 65% of patients with Richter’s transformation — a kind of diffuse large B-cell lymphoma (DLBCL) with very poor prognosis, derived ... Read more

November 16, 2018

Opdivo Plus ASCT Ably Treats Classical Hodgkin’s Lymphoma Patients with Few Options, Study Says

News

Classical Hodgkin’s lymphoma patients who failed to respond to autologous stem cell transplant (patient-derived cells) showed “unprecedented” low relapse rates after being given Opdivo (nivolumab) followed by an allogeneic, or donor-derived, ... Read more

September 8, 2017September 10, 2017

FDA Places Holds on Imfinzi Trials Following Unexplained Deaths in Keytruda Trials

News

The U.S. Food and Drug Administration (FDA) has placed a partial hold on two clinical trials testing a combination of AstraZeneca‘s Imfinzi (durvalumab) with an immunomodulatory drug in lymphoma and leukemia patients. ... Read more

June 30, 2017June 30, 2017

85% of Hodgkin Lymphoma Patients Respond to Adcetris-Opdivo Combo, Trial Shows

News

A combination of Adcetris (brentuximab vedotin) and Opdivo (nivolumab) led to Hodgkin lymphoma diminishing in 85 percent of patients in a Phase 1/2 trial (NCT02572167), researchers reported. Among them, 63 ... Read more

June 7, 2017

Phase 3 Study Soon to Test Opdivo and Adcetris Combo in Treating Relapsed Hodgkin’s Lymphoma Patients

News

Combining Bristol-Myers Squibb’s checkpoint inhibitor Opdivo (nivolumab) with Seattle Genetics’ antibody-therapy conjugate Adcetris (brentuximab vedotin) has been shown to be effective and safe in people with recurrent Hodgkin’s lymphoma (HL). Based on these ... Read more

March 8, 2017March 8, 2017

Opdivo May Treat Hodgkin Lymphoma Patients Who Relapse After Stem Cell Transplant

News

The immune checkpoint inhibitor Opdivo (nivolumab) may induce remission in classical Hodgkin lymphoma (cHL) patients who have relapsed following an allogeneic hematopoietic stem cell transplant. That was the conclusion of a new ... Read more

December 21, 2016

Opdivo May Help Those With Two Types of Non-Hodgkin’s Lymphoma

News

The FDA-approved Hodgkin’s-lymphoma treatment Opdivo (nivolumab) may also be effective against primary central nervous system lymphoma (PCNSL) or primary testicular lymphoma (PTL), case studies suggest. Researchers presented the results at ... Read more

August 29, 2016August 29, 2016

Opdivo Shows Potential in Specific Hodgkin’s Lymphoma Patients Whose Disease Progressed After Bone Marrow Transplant

News

Patients with classical Hodgkin’s lymphoma who progressed after receiving autologous hematopoietic stem cell transplant (HSCT) and treatment with Adcetris (brentuximab vedotin) may benefit from the PD-1 inhibitor Opdivo (nivolumab), according ... Read more

May 19, 2016May 19, 2016

FDA Approves Opdivo (nivolumab) to Treat Advanced Classical Hodgkin Lymphoma

News

The U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab), a PD-1 inhibitor, for the treatment of classical Hodgkin lymphoma (cHL) in patients who relapsed or progressed after autologous hematopoietic stem ... Read more

April 4, 2016May 13, 2016

EMA Agrees to Consider Opdivo (nivolumab) as a Possible Treatment for Classical Hodgkin’s Lymphoma

News

Bristol-Myers Squibb announced that the European Medicines Agency (EMA) has validated its Type II variation application of Opdivo (nivolumab), which seeks to extend Opdivo’s current indications to include the treatment of classical Hodgkin’s lymphoma (cHL) patients after prior therapies. The ... Read more